User: Guest  Login
Title:

[Update 2016 - Immunotherapy for urothelial carcinoma].

Document type:
Journal Article; Review; Article
Author(s):
Retz, M; Gschwend, J E; Schmid, S C
Abstract:
Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.
Journal title abbreviation:
Urologe A
Year:
2016
Journal volume:
55
Journal issue:
2
Pages contribution:
246-52
Language:
de
Fulltext / DOI:
doi:10.1007/s00120-015-0024-y
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/26767648
Print-ISSN:
0340-2592
TUM Institution:
Urologische Klinik und Poliklinik
 BibTeX